solifenacin + tamsulosin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
solifenacin + tamsulosin: clinical details
Prescribing considerations
- Confirm that symptoms are consistent with benign prostatic hyperplasia and exclude other causes, including urinary infection, renal disease and heart failure.
- Assess renal and hepatic function and review CYP3A4 and CYP2D6 inhibitors before prescribing.
- Evaluate baseline risk of urinary retention, gastrointestinal obstruction or reduced gastrointestinal motility.
- Review anticholinergic burden and susceptibility to confusion, constipation, blurred vision or falls.
- Ask about planned or previous cataract or glaucoma surgery and inform the ophthalmic team of current or previous tamsulosin exposure.
- Consider QT-risk factors such as congenital long-QT syndrome, hypokalaemia and interacting medicines.
Contraindications and cautions
- Hypersensitivity to either active ingredient or an excipient
- Haemodialysis
- Severe hepatic impairment
- Severe renal impairment with a strong CYP3A4 inhibitor
- Moderate hepatic impairment with a strong CYP3A4 inhibitor
- Severe gastrointestinal conditions, including toxic megacolon
- Myasthenia gravis
- Narrow-angle glaucoma or significant risk of it
- History of orthostatic hypotension
Monitoring
- Storage and voiding symptom response and continued treatment need
- Difficulty passing urine or increasing post-void symptoms
- Postural dizziness, blood pressure-related symptoms and falls
- Constipation and other antimuscarinic adverse effects
- Renal and hepatic status where clinically indicated
- New interacting medicines and cumulative anticholinergic burden
Clinical pharmacology
Solifenacin is a competitive muscarinic-receptor antagonist with greatest affinity for M3 receptors. Tamsulosin selectively antagonises alpha-1A and alpha-1D adrenoceptors in lower urinary tract tissues. Both are principally metabolised through CYP3A4; tamsulosin also involves CYP2D6.
Formulation and product differences
- The selected product is a fixed-combination, film-coated modified-release tablet containing separate solifenacin and tamsulosin layers.
- The tablet must remain intact and is unsuitable for crushing or chewing.
- The fixed combination does not allow either component to be adjusted independently.
solifenacin + tamsulosin preparations and strengths
Modified-release tablet
Route: Oral
Strengths: 6 mg + 0.4 mg
solifenacin + tamsulosin interactions
Check the full medication list, including non-prescription and herbal products. Important examples include:
Strong or moderate CYP3A4 inhibitors, including ketoconazole, itraconazole, ritonavir and verapamil
Can increase exposure to both components and increase adverse effects; some combinations are contraindicated in renal or hepatic impairment or with strong CYP2D6 inhibition.
Other antimuscarinic or anticholinergic medicines
Can increase dry mouth, constipation, blurred vision, cognitive effects and urinary retention.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.